Hospital Raja Perempuan Zainab II

Kota Bharu, Kelantan 15586

0 studies enrolling now · 17 studies all time

What they study most

Acute Myocardial Infarction (AMI), Adjuvant, Adnexal Mass, COVID-19, Cardiovascular Risk, Chronic Kidney Disease, Chronic Kidney Diseases, Crohn Disease, Deep Vein Thrombosis (DVT), Diabetes Mellitus, Type 2, EGFR, Early Stage Lung Cancer

Studies at this site

• ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis — Recruiting now
• A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight — Withdrawn before enrolling
• A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes — Completed
• Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) — Stopped early
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) — Completed
• Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy — Completed
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). — Stopped early
• A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures — Completed
• A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis — Completed
• A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1 — Stopped early